Xi Venture Capital participates in Yituo Pharmaceutical's B+round financing

　　Today, Etern Therapeutics, which focuses on the research and development of small molecule drugs targeting protein liquid-liquid phase separation, announced the completion of its B+round of financing. Xi Venture Capital, together with AstraZeneca and Wuxi Xintou Group, participated in this round of financing. After the financing is completed, Yituo Pharmaceutical will accelerate the construction of the LLPS protein liquid-liquid phase separation technology platform and continue to promote the early development and clinical research of the company's projects.

　　Yituo Pharmaceutical is a biopharmaceutical company that focuses on the research and development of small molecule drugs targeting protein liquid-liquid phase separation. It has globally leading technology, a top R&D team, and a strong foundation of cooperation with multinational pharmaceutical companies. It is full of innovation and explosive power. Yituo Pharmaceutical has set up a research and development headquarters in Wuxi High tech Zone, established a platform for the transformation of cross disciplinary research results in biology and chemistry, and hired research talents from top universities to build an internationally first-class phase separation technology research platform. Yituo Pharmaceutical has independently developed the world's leading protein liquid-liquid phase separation technology platform - LLPS platform. This platform integrates AI enabled phase separation target discovery, high-throughput high content drug screening, and drug optimization technologies, providing new perspectives and strategies for innovative drug development, especially for drug development targeting "difficult to drug" targets.